Insulet Corporation
Price Chart
Financials
※ FY = Fiscal Year
Investment Metrics(as of 2026-06-18)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | $10.10B |
| Revenue | $2.90B |
| Net Income | $303M |
| Total Assets | $2.99B |
| Net Assets | $1.30B |
| Employees | 5,400 |
| Value | |
| P/E | 33.34x |
| P/B | 7.75x |
| PEG | 0.21x |
| P/S | 3.48x |
| EV/EBITDA | 18.81x |
| FCF Yield | 4.08% |
| Profitability | |
| ROE | 23.25% |
| ROA | 10.14% |
| Op. Margin | 17.48% |
| Revenue Growth | 33.87% |
| Earnings Growth | 157.34% |
| Financial Health | |
| Debt Ratio | 129.33% |
| Total Debt | $948M |
| FCF | $412M |
| Cash | $480M |
| Current Ratio | 2.49x |
| Net Debt/EBITDA | 0.83x |
| Performance | |
| 1Y Return | -51.70% |
| 1M Return | -5.73% |
| From 52W High | -58.93% |
| 1Y MDD | -59.63% |
| Trading | |
| Volume | 1,108,978 shares |
| Trading Value | $160M |
| Per Share | |
| EPS | $3.51 |
| BPS | $21.53 |
Company Info
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.